iBio Discovers New Panel of CD3 TCell Binding Antibodies Using its Patented AI Epitope Steering Platform

BRYAN, Texas, April 04, 2023 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced that a presentation given today by its VP & Head of Machine Learning & Platform Technologies, Matt Greving, Ph.D., during Carterra’s “Unlocking High-Throughput Biology and Drug Discovery” symposium in San Diego, CA, revealed the discovery of a panel of CD3 T-cell binding antibodies, representing an important first step for the Company into bispecific immuno-oncology therapies. T-cell-redirecting bispecific antibodies are a new class of therapeutic antibodies designed to simultaneously bind to T cells via CD3 and to tumor…